Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead.
AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.
Overview
Ken Griffin recently boosted stakes in AbbVie (NYSE: ABBV) and Abbott Laboratories (NYSE: ABT), according to his latest 13F. Griffin is the billionaire founder and CEO of the hedge fund company Citadel. Arguably one of the sharpest minds in the hedge-fund world, he is leaning into two healthcare machines that sit right at the intersection of science and steady cash; that's a signal worth thinking about.
Griffin's portfolio holds over 1,000 positions and hundreds of billions of dollars. He can put money almost anywhere. Yet he raised his exposure to AbbVie, a drug developer built on immunology and oncology, and Abbott, a device and diagnostics giant embedded in hospitals and homes across the globe.
Details
That tells me he wants a core slice of healthcare that can keep working through many market moods. Let's see if investors should follow his lead.
Source
Originally published at www.fool.com.